Inivata is a leader in liquid biopsy whose InVision platform unlocks genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Its lead commercial product, InVisionFirst®-Lung, is available internationally and through NeoGenomics in the U.S. The company has also launched RaDaR™, a personalized, highly sensitive assay for detecting minimal residual disease (MRD) and recurrence, initially applied in clinical-trial settings. Inivata partners with pharmaceutical and biotechnology companies across early and late-stage cancer development programs to deploy its assays. The company operates a CLIA-certified, CAP-accredited laboratory in Research Triangle Park, NC, and R&D laboratories in Cambridge, UK. Recent financing activity (Series C closings) is intended to accelerate clinical development of RaDaR and expand commercialization of InVisionFirst-Lung. Inivata develops the InVision® liquid biopsy platform and the commercially available InVisionFirst™-Lung test, which uses a simple blood draw to detect clinically relevant cancer mutations. The InVisionFirst-Lung test recently received a coverage determination for US Medicare patients with advanced non-small cell lung cancer (NSCLC). The company plans to use new funding to advance the US commercial roll-out of InVisionFirst-Lung and to accelerate development of the InVision platform into new indications. Inivata completed a $52.6m Series B that was over-subscribed, with a first close in August 2018 and a final tranche received in March 2019. The company is led by CEO Clive Morris and operates a CLIA laboratory in Research Triangle Park, NC, with additional laboratories in Cambridge, UK. Inivata provides a ctDNA analysis platform based on an enhanced TAm-Seq approach that enables non‑invasive molecular profiling from a simple blood draw. The test is designed to detect cancer-related mutations to guide therapy selection, monitor treatment response, and detect emerging mutations. The company plans to apply the platform across a spectrum of solid tumors, initially including lung, breast and colon cancer, to integrate genomic information with clinically actionable decision-making. Inivata’s technology is based on research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute. Led by CEO Michael Stocum, the company intends to use recent funding to accelerate clinical studies validating the platform and to commercialize its first products. In January 2016 Inivata completed a significant Series A financing to support these plans. Inivata is a clinical cancer genomics company based in Cambridge, UK, led by CEO Michael Stocum. The company focuses on harnessing circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment through collaborations with clinical oncologists at academic institutions, community treatment centres and biopharmaceutical companies. Its technology platform includes a proprietary, enhanced TAm-Seq™ technology licensed to Inivata from Cancer Research Technology and the University of Cambridge. TAm-Seq allows detection and analysis of genomic material from a cancer patient’s cell-free ctDNA collected through routinely accessible blood samples. The article reports that Inivata raised £4m in funding.

Total raised

$139M

Funding rounds

4

Latest round

Series C

Latest activity

Feb 2021